Composition of artemisinin derivative and vinorelbine, and use thereof

Abstract

The invention relates to a composite of an artemisinin derivative and vinorelbine in the technical field of pharmaceuticals and the application thereof; wherein, the ratio of the artemisinin derivative (including dihydroartemisinin or artesunate) and the vinorelbine is 1:500 to 500:1. The composite can be applied to preparing antineoplastics and made into the dosage forms of injection administration and oral administration by adding pharmaceutically acceptable adjuvant carriers. The two effective components (the artemisinin derivative and the vinorelbine) of the composite not only have obvious synergistic effect and but also can be cooperatively applied so as to reduce the amount of the vinorelbine and lower the production cost. By adding the pharmaceutically acceptable adjuvant carriers to prepare the dosage forms of injection administration and oral administration, the composite can be applied to the anti-tumor field.

Description

technical field The invention relates to a composition in the technical field of medicine and its application, in particular to a composition of an artemisinin derivative and vinorelbine and its application. Background technique At present, malignant tumor is one of the most serious diseases threatening human health, and chemotherapy is an important means of tumor clinical treatment. Vinorelbine (vinorelbine) is a semi-synthetic vinca alkaloid, which has been used for the treatment of non-small cell lung cancer, and the effective rate of single drug application is 14%-33%. The efficiency is 36% to 52%. The drug also has a good curative effect on breast cancer, and the effective rate is between 35% and 52%, and the curative effect is improved when combined with adriamycin. In addition, vinorelbine also has a considerable effect on ovarian cancer and lymphoma. In view of the ubiquitous phenomenon of resistance to chemotherapy drugs in malignant tumors, if vinorelbine can be...

AI Technical Summary

Problems solved by technology

For example, in the Chinese patent: the application of dihydroartemisinin in enhancing the antitumor efficacy of chemotherapy drugs (application number: 200710071185.5), although it requires the protection scope of "the application of dihydroartemisinin in enhancing the antitumor efficacy of chemotherapy drugs" , but the description in the instruction manual is only for the study of the synergistic effect of dihydroartemisinin and cyclophosphamide, and does not involve the synergistic effect of dihydroartemisinin and other chemotherapeutic drugs such as vinorelbine, and this effect There are no other research reports

Images